← All stocks

Seaport Therapeutics, Inc.

SPTX Net buying

CIK 0002042347 #2373 in the set updated 17 Sep 2026

Bought (12 mo)

$20.04M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$0.00

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$0.00

0 of 0 sales

Net

+$20.04M

+$20.04M against sales at will

By person

10 insiders · 2 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

ARCH Venture Partners XII, LLC entity

10% owner

$19.80M (1)

—

+$19.80M

6,294,951

11.76%

$114.17M

—

HOMBACH ROBERT J.

Director

$235.77K (1)

—

+$235.77K

13,000

0.0243%

$235.77K

—

PureTech Health plc entity

10% owner

—

16,685,013

31.17%

$302.60M

+5,416%

HEALY JAMES

Director

—

2,731,538

5.10%

$49.54M

—

PAUL STEVEN M

Director

—

863,031

1.61%

$15.65M

+8.4%

Gladstein Lana

General Counsel

—

33,515

0.0626%

$607.83K

—

Loebel Antony

Chief Medical Officer

—

20,109

0.0376%

$364.70K

—

Torres Denice

Director

—

13,406

0.0250%

$243.13K

—

White Lauren

Chief Financial Officer

—

6,702

0.0125%

$121.55K

—

Chen Michael Cunyuan

Chief Scientific Officer

—

3,351

0.0063%

$60.77K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

HOMBACH ROBERT J.

22 Jun 2026

Director

Buy indirect

13,000

$18.14

$235.77K

ARCH Venture Partners XII, LLC

4 May 2026

10% owner

Buy indirect

1,100,000

$18.00

$19.80M

What was left out

Form 4 filings counted 15

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 2

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 24,453,137

History held since 4 May 2026